Abstract:

Patient characteristics between the positive and negative populations of T790M were compared and the prognosis was studied in patients with re-biopsy by analyzing post-progressive survival (PPS) after the first thyrozine kinase inhibitor (TKI) failure. Methods and Requirements: The characteristic characteristics of patients, the EGFR-TKI response, the EGFR status during rebiopsy or liquid biopsy, the pre-rebiopsy treatment (chemotherapy/EGFR-TKI), the first EGFR-TKI resistance development and the biopsy time (first EGFR-TKI failure) were studied. There is no difference between age, gender, and metastasis between the two positive and negative groups of T790M mutations. In patients with only T790M mutation positive, the post-TKI progression was shown to be greater than in patients with negative mutation (p: 0.001). In patients using TDI, progressive median survival T790M mutation was identified as 22.25 months in the negative group, while 19.33 months in the group. The overall survival of T790M was found at 75 months and 27,5 months respectively in the positive and negative group, and this was statistically meaningful (p: 0.009). The overall survival of the T790M in the positive group, the T790M in the negative group was statistically significant at a long level. In addition, fluid biopsy can be performed several times in patients with post-EGFR-TKI progression and who do not want to make tissue biopsy.

Keywords: